Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: A meta-analysis of 5,821 patients

Cardiology (Switzerland)

Volumn 122, Issue 3, 2012, Pages 148-157

  Geng, Deng Feng ^a   Liu, Mo ^a   Jin, Dong Mei ^a   Wu, Wei ^a   Deng, Jing ^a   Wang, Jing Feng ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Acute coronary syndrome; Antiplatelet therapy; Cilostazol; Coronary stenting

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS CLOPIDOGREL; CILOSTAZOL; CLOPIDOGREL; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ARTICLE; BARE METAL STENT; BLEEDING; CARDIAC PATIENT; CORONARY ARTERY RECANALIZATION; CORONARY STENT; DIABETES MELLITUS; DIABETIC PATIENT; DRUG ELUTING STENT; DRUG FATALITY; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; HEADACHE; HEART DEATH; HEART INFARCTION; HEART PALPITATION; HIGH RISK PATIENT; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RESTENOSIS; RISK; STENT THROMBOSIS;

ACUTE CORONARY SYNDROME; ASPIRIN; BLOOD VESSEL PROSTHESIS; BLOOD VESSEL PROSTHESIS IMPLANTATION; CORONARY RESTENOSIS; DRUG THERAPY, COMBINATION; HEMORRHAGE; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STENTS; STROKE; TETRAZOLES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84864096297     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000338812     Document Type: Article

References (44)

1. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, McDermott MM, Meigs JB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Rosamond WD, Sorlie PD, Stafford RS, Turan TN, Turner MB, Wong ND, Wylie-Rosett J, American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011; 123:e18-e209.
2. US Food and Drug Administration, Circulatory System Devices Panel: Meeting minutes, Washington, December 2006. http://www. fda.gov/ohrms/docket s/ac/06/transcripts/2006-4253t2.rtf (accessed September 28, 2010).
3. Lee CW, Park DW, Lee BK, Kim YH, Hong MK, Kim JJ, Park SW, Park SJ: Predictors of restenosis after placement of drug-eluting stents in one or more coronary arteries. Am J Cardiol 2006; 97: 506-511. (Pubitemid 43190041)
4. Kastrati A, Dibra A, Mehilli J, Mayer S, Pinieck S, Pache J, Dirschinger J, Schömig A: Predictive factors of restenosis after coronary implantation of sirolimus-or paclitaxel-eluting stents. Circulation 2006; 113: 2293-2300. (Pubitemid 43947975)
5. Hong SJ, Kim MH, Ahn TH, Ahn YK, Bae JH, Shim WJ, Ro YM, Lim D-S: Multiple predictors of coronary restenosis after drugeluting stent implantation in patients with diabetes. Heart 2006; 92: 1119-1124. (Pubitemid 44125234)
6. Kambayashi J, Liu Y, Sun B, Shakur Y, Yoshitake M, Czerwiec F: Cilostazol as a unique antithrombotic agent. Curr Pharm Des 2003; 9: 2289-2302. (Pubitemid 37236353)
7. Geng DF, Deng J, Jin DM, Wu W, Wang JF: Effect of cilostazol on the progression of carotid intima-media thickness: a meta-analysis of randomized controlled trials. Atherosclerosis 2012; 220: 177-183.
8. Lee SW, Chun KJ, Park SW, Kim HS, Kim YH, Yun SC, Kim WJ, Lee JY, Park DW, Lee CW, Hong MK, Rhee KS, Chae JK, Ko JK, Park JH, Lee JH, Choi SW, Jeong JO, Seong IW, Jon S, Cho YH, Lee NH, Kim JH, Park SJ: Comparison of triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and DECLARE-LONG Trials). Am J Cardiol 2010; 105: 168-173.
9. Suh JW, Lee SP, Park KW, Lee HY, Kang HJ, Koo BK, Cho YS, Youn TJ, Chae IH, Choi DJ, Rha SW, Bae JH, Kwon TG, Bae JW, Cho MC, Kim HS: Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. J Am Coll Cardiol 2011; 57: 280-289.
10. The Cochrane Collaboration: Cochrane Handbook for Systematic Reviews of Interventions 5.1.0., updated March 2011.
11. Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, Grines CL, Block E, Ghazzal ZM, Morris DC, Liberman H, Parker K, Jurkovitz C, Murrah N, Foster J, Hyde P, Mancini GB, Weintraub WS, Cilostazol for Restenosis Trial (CREST) Investigators: Coronary stent restenosis in patients treated with cilostazol. Circulation 2005; 112: 2826-2832. (Pubitemid 41641677)
12. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Hong MK, Kim HS, Ko JK, Park JH, Lee JH, Choi SW, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Park SJ: Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (a randomized comparison of triple antiplatelet therapy with dual antiplatelet therapy after drug-eluting stent implantation in diabetic patients). J Am Coll Cardiol 2008; 51: 1181-1187. (Pubitemid 351382092)
13. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Hong MK, Kim HS, Ko JK, Park JH, Lee JH, Choi SW, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Park SJ, DECLARE-LONG Study Investigators: Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-LONG trial). Am J Cardiol 2007; 100: 1103-1108. (Pubitemid 47404466)
14. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Kang SJ, Park SJ, Lee JH, Choi SW, Seong IW, Lee NH, Cho YH, Shin WY, Lee SJ, Lee SW, Hyon MS, Bang DW, Choi YJ, Kim HS, Lee BK, Lee K, Park HK, Park CB, Lee SG, Kim MK, Park KH, Park WJ, DECLARE-LONG II Study Investigators: A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with long coronary lesions) trial. J Am Coll Cardiol 2011; 57: 1264-1270.
15. Min PK, Jung JH, Ko YG, Choi D, Jang Y, Shim WH: Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting: a quantitative coronary angiography and volumetric intravascular ultrasound study. Circ J 2007; 71: 1685-1690. (Pubitemid 350240086)
16. Ahn CM, Hong SJ, Park JH, Kim JS, Lim DS: Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year followup. Heart Vessels 2011; 26: 502-510.
17. Han Y, Li Y, Wang S, Jing Q, Wang Z, Wang D, Shu Q, Tang X: Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J 2009; 157: 733-739.
18. Chen YD, Lu YL, Jin ZN, Yuan F, Lü SZ: A prospective randomized antiplatelet trial of cilostazol versus clopidogrel in patients with bare metal stents. Chin Med J (Engl) 2006; 119: 360-366. (Pubitemid 43796888)
19. Lu YL, Chen YD, Lv SZ: Effect of intensive antiplatelet therapy in patients with high platelet aggregability after percutaneous coronary intervention. Chin J Cardiol 2007; 35: 793-796.
20. Wang SL, Han YL, Jin QM, Wang ZL, Wang DM, Deng J, Yang GT, Yu HB: Long-term effects of cilostazol on clinical outcomes after coronary stent implantation in small vessel lesions. J Fourth Mil Med Univ 2005; 26: 994-997.
21. Wang SL, Sun F, Zhao X, Chen LL, Feng GB, Yan CH, Han YL: Effect of percutaneous coronary intervention timing and cilostazol use on left ventricular remodeling in patients with non-ST elevation myocardial infarction. Zhonghua Xin Xue Guan Bing Za Zhi 2010; 38: 870-874.
22. Lu YL, Chen YD, Lv SZ, Pan WQ, Liu X: Effect of cilostazol on restenosis in elderly patients with coronary bare-metal stents implantation. Chin J Geriatr 2006; 25: 537-578.
23. Park SJ, Long-DES-II Study Investigators: Percutaneous treatment of LONG native coronary lesions with drug-eluting stent-II: cypher versus taxus, LONG-DES-II. http://www.crtonline.org/flash.aspx?PAGE-ID=3397 (accessed June 1, 2011).
24. Biondi-Zoccai GG, Lotrionte M, Anselmino M, Moretti C, Agostoni P, Testa L, Abbate A, Cosgrave J, Laudito A, Trevi GP, Sheiban I: Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention. Am Heart J 2008; 155: 1081-1089.
25. Lee SW, Park SW, Yun SC, Kim YH, Park DW, Kim WJ, Lee JY, Lee CW, Hong MK, Kim JJ, Park SJ: Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: drug-Eluting stenting followed by cilostazol treatment reduces adverse serious cardiac events (DECREASE registry). Am Heart J 2010; 159: 284-291.
26. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV: Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007; 167: 1593-1599. (Pubitemid 47280339)
27. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV: Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007; 154: 221-231. (Pubitemid 47069129)
28. Jeong YH, Lee SW, Choi BR, Kim IS, Seo MK, Kwak CH, Hwang JY, Park SW: Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (adjunctive cilostazol versus high maintenance dose clopidogrel in patients with clopidogrel resistance) randomized study. J Am Coll Cardiol 2009; 53: 1101-1109.
29. Frossard M, Fuchs I, Leitner JM, Hsieh K, Vlcek M, Losert H, Domanovits H, Schreiber W, Laggner AN, Jilma B: Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 2004; 110: 1392-1397. (Pubitemid 39238016)
30. Kim JY, Lee K, Shin M, Ahn M, Choe H, Yoo BS, Yoon J, Choe KH, Lee SH: Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention. Circ J 2007; 71: 1867-1872. (Pubitemid 350261408)
31. Pattanaik S, Malhotra S, Sharma YP, Ahluwalia J, Bhalla A, Pandhi P: Effect of cilostazol on platelet aggregation in patients with non-ST elevation acute coronary syndrome. Int J Clin Pharmacol Ther 2010; 48: 93-102.
32. Jeong YH, Hwang JY, Kim IS, Park Y, Hwang SJ, Lee SW, Kwak CH, Park SW: Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCELAMI) study. Circ Cardiovasc Interv 2010; 3: 17-26.
33. Chen KY, Rha SW, Li YJ, Poddar KL, Jin Z, Minami Y, Wang L, Kim EJ, Park CG, Seo HS, Oh DJ, Jeong MH, Ahn YK, Hong TJ, Kim YJ, Hur SH, Seong IW, Chae JK, Cho MC, Bae JH, Choi DH, Jang YS, Chae IH, Kim CJ, Yoon JH, Chung WS, Seung KB, Park SJ, Korea Acute Myocardial Infarction Registry Investigators: Triple versus dual antiplatelet therapy in patients with acute STsegment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 2009; 119: 3207-3214.
34. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators: Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015. (Pubitemid 350106708)
35. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, PLATO Investigators, Freij A, Thorsén M: Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
36. Kobayashi Y, De Gregorio J, Kobayashi N, Akiyama T, Reimers B, Finci L, Di Mario C, Colombo A: Stented segment length as an independent predictor of restenosis. J Am Coll Cardiol 1999; 34: 651-659. (Pubitemid 29436167)
37. Akiyama T, Moussa I, Reimers B, Ferraro M, Kobayashi Y, Blengino S, Di Francesco L, Finci L, Di Mario C, Colombo A: Angiographic and clinical outcome following coronary stenting of small vessels: a comparison with coronary stenting of large vessels. J Am Coll Cardiol 1998; 32: 1610-1618. (Pubitemid 28545198)
38. Lee SW, Park SW, Hong MK, Kim YH, Lee BK, Song JM, Han KH, Lee CW, Kang DH, Song JK, Kim JJ, Park SJ: Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol 2005; 46: 1833-1837. (Pubitemid 41579804)
39. Kim JS, Lee KS, Kim YI, Tamai Y, Nakahata R, Takami H: A randomized crossover comparative study of aspirin, cilostazol and clopidogrel in normal controls: analysis with quantitative bleeding time and platelet aggregation test. J Clin Neurosci 2004; 11: 600-602. (Pubitemid 38916968)
40. Angiolillo DJ, Capranzano P, Ferreiro JL, Ueno M, Capodanno D, Dharmashankar K, Darlington A, Sumner S, Desai B, Charlton RK, Box LC, Zenni M, Guzman LA, Bass TA: Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy. Thromb Haemost 2011; 106: 253-262.
41. Singh I, Shafiq N, Pandhi P, Reddy S, Pattanaik S, Sharma Y, Malhotra S: Triple antiplatelet therapy vs. dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: an evidence-based approach to answering a clinical query. Br J Clin Pharmacol 2009; 68: 4-13.
42. Jennings DL, Kalus JS: Addition of cilostazol to aspirin and a thienopyridine for prevention of restenosis after coronary artery stenting: a meta-analysis. J Clin Pharmacol 2010; 50: 415-421.
43. Tamhane U, Meier P, Chetcuti S, Chen KY, Rha SW, Grossman MP, Gurm H: Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials. EuroIntervention 2009; 5: 384-393.
44. Takagi H, Umemoto T: A meta-analysis of randomized trials of triple versus dual antiplatelet therapy after stent-based percutaneous coronary intervention. Int J Cardiol 2011; 150: 228-230.